Biotech Business - January 3, 2018
Alligator to receive USD 6 million in milestone payment
Alligator Bioscience announces that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc. The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen’s proprietary PD-1 inhibitors. This is the first out of a number […]
Collaboration - January 3, 2018
Unique genetic study launched in Finland
The research study, FinnGen, plans to tap into 500 000 unique blood samples collected by a nation-wide network of Finnish biobanks and aims to deepen our understanding about the origins of diseases and their treatment. ”All breakthroughs that arise from the project will eventually benefit health care systems and patients both locally and globally. The […]
Collaboration - December 21, 2017
How Turku helps life science companies grow faster
Turku combines a strong local R&D ecosystem with a large talent pool and national efforts for global breakthrough in life science. Since the 1940s the city of Turku has had a strong drug development and diagnostics industry. Through academic research and companies with R&D expertise, Turku has gained a key position in the development of […]
Collaboration - December 19, 2017
More clinical-academic collaborations are in the future for Odense
With a new hospital being built near a university, more clinical-academic collaborations are in the future for Odense. The picturesque old town of Odense features the home of Hans Christian Andersen, the world-famous fairy tale writer from the 1800s. But only 10 km away, an ambitious, modern life sciences enterprise is developing. The New University Hospital […]
Biotech Business - December 7, 2017
BioInvent and Transgene collaborate
BioInvent International and Transgene have entered a collaboration to co-develop next generation oncolytic virus (OV) candidates encoding an anti-CTLA-4 antibody sequence – potentially with additional transgenes – capable of treating multiple solid tumors. Under the terms of the agreement Transgene will contribute both its OV design and engineering expertise as well as its engineered Vaccinia virus, derived […]
Business article - November 30, 2017
Antibiotic advances from New Drugs 4 Bad Bugs
Public-private partnerships are addressing the major challenges of microbial drug resistance. In 2016, a woman in the United States died from a bacterial strain resistant to 26 antibiotics. Recently, The Lancet reported on a dangerously resistant strain in China. The World Health Organization says that antimicrobial resistance (AMR) is a global emergency. Countering this worrying trend is the public-private program New Drugs 4 Bad Bugs […]
